Cardiovascular Safety of ??2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 21 (6) , 405-414
Abstract
β2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality. A systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD. Case-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo. Initiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.Keywords
This publication has 99 references indexed in Scilit:
- Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Influence of Heart Rate on Mortality in a French PopulationHypertension, 1999
- The acute effects of inhaled salbutamol on the beat‐to‐beat variability of heart rate and blood pressure assessed by spectral analysisBritish Journal of Clinical Pharmacology, 1997
- Risks Versus Benefits of Inhaled ??2-Agonists in the Management of AsthmaDrug Safety, 1992
- AtenololDrugs, 1991
- Oral Terbutaline Augments Cardiac Performance in Chronic Obstructive Pulmonary DiseaseThe American Journal of the Medical Sciences, 1988
- Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction.Circulation, 1985
- Fenoterol in asthmaRespiratory Medicine, 1979
- Some Aspects of the Pharmacology of β-Adrenoreceptor BlockersDrugs, 1976
- Clinical effects of epinephrine by inhalationJournal of Allergy, 1948